Anti-TNFα agents increase risk of infections due to systemic immunosuppression. Vedolizumab (VDZ) inhibits adhesions of gut-specific lymphocytes and thus may carry a lower risk. However, its safety in patients with prior tuberculosis (TB) infection is not known. We report a patient who developed TB while on anti-TNFα and was later safely maintained on VDZ.